Bard C R Inc's Revenue in the fiscal year 2016 $ 3,714.00 millions
Bard C R Inc's Revenue in the fiscal year 2015 $ 3,416.00 millions
Bard C R Inc's Revenue in the fiscal year 2014 $ 3,323.60 millions
Bard C R Inc's Revenue in the fiscal year 2013 $ 3,049.50 millions
Bard C R Inc's Revenue in the fiscal year 2012 $ 2,958.10 millions
BCR Revenue third quarter 2017 Y/Y Growth Comment
Bard C R Inc reported Revenue growth of 5.09% year on year in the third quarter 2017, to $ 989.80 millions, this is lower than Bard C R Inc's recent average Revenue growth of 7.04%.
Looking into third quarter 2017 results within Medical Equipment & Supplies industry 94 other companies have achieved higher Revenue growth. While Bard C R Inc' s Revenue increase of 5.09% ranks overall at the positon no. 2268 in the third quarter 2017.
Revenue by Quarter for the Fiscal Years 2014, 2015, 2016, 2017
Bard C R Inc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
9.66 %
1.73 %
-9.11 %
(Dec 31 2016)
BCR's III. Quarter Q/Q Revenue Comment
Bard C R Inc achieved in the III. Quarter 2017 below company average Revenue growth of 1.03% quarter on quarter, to $ 989.80 millions.
Within Medical Equipment & Supplies industry 73 other companies have achieved higher Revenue quarter on quarter growth. While Bard C R Inc's Revenue growth quarter on quarter, overall rank is 2208.
Bard C R Inc achieved in the III. Quarter 2017 below company average Revenue growth of 1.03% quarter on quarter, to $ 989.80 millions.
Within Medical Equipment & Supplies industry 73 other companies have achieved higher Revenue quarter on quarter growth. While Bard C R Inc's Revenue growth quarter on quarter, overall rank is 2208.
Bard C R Inc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Sep 30 2017)
12 Months Ending (Jun 30 2017)
12 Months Ending (Mar 31 2017)
12 Months Ending (Dec 31 2016)
12 Months Ending (Sep 30 2016)
Cumulative Revenue 12 Months Ending
$ 3,875.40
$ 3,827.50
$ 3,779.30
$ 3,714.00
$ 3,617.70
Y / Y Revenue Growth (TTM)
7.12 %
8.08 %
8.92 %
8.72 %
6.02 %
Year on Year Revenue Growth Overall
Ranking
# 1855
# 1406
# 1221
# 1223
# 1437
Seqeuential Revenue Change (TTM)
1.25 %
1.28 %
1.76 %
2.66 %
2.15 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2161
# 194
# 175
# 1822
# 2034
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2017 period, Bard C R Inc's cumulative twelve months Revenue were $ 3,875 millions, company would post below average annual Revenue growth of 2.15% year on year, if the fiscal year would end at Sep 30 2017. A slow-down in the Bard C R Inc's Revenue growth from the 979.7% growth in Jun 30 2017.
In the Healthcare sector 255 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1406 to 1855.
With the quarterly Revenue reported in the Sep 30 2017 period, Bard C R Inc's cumulative twelve months Revenue were $ 3,875 millions, company would post below average annual Revenue growth of 1.43% year on year, if the fiscal year would end at Sep 30 2017. A slow-down in the Bard C R Inc's Revenue growth from the 979.7% growth in Jun 30 2017.
In the Healthcare sector 255 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1406 to 1855.
About Bard C R Inc Revenue Growth Rates (BCR), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
8.75%